Literature DB >> 18955474

Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model.

Crystal L Loving1, Taruna Khurana, Manuel Osorio, Gloria M Lee, Vanessa K Kelly, Scott Stibitz, Tod J Merkel.   

Abstract

Anthrax toxins significantly contribute to anthrax disease pathogenesis, and mechanisms by which the toxins affect host cellular responses have been identified with purified toxins. However, the contribution of anthrax toxin proteins to dissemination, disease progression, and subsequent immunity after aerosol infection with spores has not been clearly elucidated. To better understand the role of anthrax toxins in pathogenesis in vivo and to investigate the contribution of antibody to toxin proteins in protection, we completed a series of in vivo experiments using a murine aerosol challenge model and a collection of in-frame deletion mutants lacking toxin components. Our data show that after aerosol exposure to Bacillus anthracis spores, anthrax lethal toxin was required for outgrowth of bacilli in the draining lymph nodes and subsequent progression of infection beyond the lymph nodes to establish disseminated disease. After pulmonary exposure to anthrax spores, toxin expression was required for the development of protective immunity to a subsequent lethal challenge. However, immunoglobulin (immunoglobulin G) titers to toxin proteins, prior to secondary challenge, did not correlate with the protection observed upon secondary challenge with wild-type spores. A correlation was observed between survival after secondary challenge and rapid anamnestic responses directed against toxin proteins. Taken together, these studies indicate that anthrax toxins are required for dissemination of bacteria beyond the draining lymphoid tissue, leading to full virulence in the mouse aerosol challenge model, and that primary and anamnestic immune responses to toxin proteins provide protection against subsequent lethal challenge. These results provide support for the utility of the mouse aerosol challenge model for the study of inhalational anthrax.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18955474      PMCID: PMC2612249          DOI: 10.1128/IAI.00633-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  61 in total

1.  Capsule synthesis by Bacillus anthracis is required for dissemination in murine inhalation anthrax.

Authors:  Melissa Drysdale; Sara Heninger; Julie Hutt; Yahua Chen; C Rick Lyons; Theresa M Koehler
Journal:  EMBO J       Date:  2004-12-16       Impact factor: 11.598

Review 2.  Protective immunity induced by Bacillus anthracis toxin mutant strains.

Authors:  C Pezard; J C Sirard; M Mock
Journal:  Adv Exp Med Biol       Date:  1996       Impact factor: 2.622

3.  Immunologic studies of anthrax. IV. Evaluation of the immunogenicity of three components of anthrax toxin.

Authors:  B G Mahlandt; F Klein; R E Lincoln; B W Haines; W I Jones; R H Friedman
Journal:  J Immunol       Date:  1966-04       Impact factor: 5.422

4.  Toxin-deficient mutants of Bacillus anthracis are lethal in a murine model for pulmonary anthrax.

Authors:  Sara Heninger; Melissa Drysdale; Julie Lovchik; Julie Hutt; Mary F Lipscomb; Theresa M Koehler; C Rick Lyons
Journal:  Infect Immun       Date:  2006-08-21       Impact factor: 3.441

Review 5.  Manipulation of host signalling pathways by anthrax toxins.

Authors:  Benjamin E Turk
Journal:  Biochem J       Date:  2007-03-15       Impact factor: 3.857

6.  Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine.

Authors:  S F Little; B E Ivins; P F Fellows; M L M Pitt; S L W Norris; G P Andrews
Journal:  Vaccine       Date:  2004-01-02       Impact factor: 3.641

7.  Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques.

Authors:  B E Ivins; M L Pitt; P F Fellows; J W Farchaus; G E Benner; D M Waag; S F Little; G W Anderson; P H Gibbs; A M Friedlander
Journal:  Vaccine       Date:  1998-07       Impact factor: 3.641

8.  Contribution of individual toxin components to virulence of Bacillus anthracis.

Authors:  C Pezard; P Berche; M Mock
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

Review 9.  The roles of anthrax toxin in pathogenesis.

Authors:  Mahtab Moayeri; Stephen H Leppla
Journal:  Curr Opin Microbiol       Date:  2004-02       Impact factor: 7.934

10.  Inhalational Anthrax.

Authors:  Erwin Kurt Cullamar; Larry I. Lutwick
Journal:  Curr Infect Dis Rep       Date:  2002-06       Impact factor: 3.663

View more
  27 in total

Review 1.  Noninvasive biophotonic imaging for studies of infectious disease.

Authors:  Nuria Andreu; Andrea Zelmer; Siouxsie Wiles
Journal:  FEMS Microbiol Rev       Date:  2010-10-19       Impact factor: 16.408

Review 2.  Role of pore-forming toxins in bacterial infectious diseases.

Authors:  Ferdinand C O Los; Tara M Randis; Raffi V Aroian; Adam J Ratner
Journal:  Microbiol Mol Biol Rev       Date:  2013-06       Impact factor: 11.056

3.  Analysis of defined combinations of monoclonal antibodies in anthrax toxin neutralization assays and their synergistic action.

Authors:  Miriam M Ngundi; Bruce D Meade; Stephen F Little; Conrad P Quinn; Cindi R Corbett; Rebecca A Brady; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

Review 4.  The Bacillus cereus Group: Bacillus Species with Pathogenic Potential.

Authors:  Monika Ehling-Schulz; Didier Lereclus; Theresa M Koehler
Journal:  Microbiol Spectr       Date:  2019-05

5.  Cellular adaptation to anthrax lethal toxin-induced mitochondrial cholesterol enrichment, hyperpolarization, and reactive oxygen species generation through downregulating MLN64 in macrophages.

Authors:  Soon-Duck Ha; Sangwook Park; Chae Young Han; Marilyn L Nguyen; Sung Ouk Kim
Journal:  Mol Cell Biol       Date:  2012-10-01       Impact factor: 4.272

6.  Noninvasive imaging technologies reveal edema toxin as a key virulence factor in anthrax.

Authors:  Fabien Dumetz; Grégory Jouvion; Huot Khun; Ian Justin Glomski; Jean-Philippe Corre; Clémence Rougeaux; Wei-Jen Tang; Michèle Mock; Michel Huerre; Pierre Louis Goossens
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

7.  Epicutaneous model of community-acquired Staphylococcus aureus skin infections.

Authors:  Ranjani Prabhakara; Oded Foreman; Roberto De Pascalis; Gloria M Lee; Roger D Plaut; Stanley Y Kim; Scott Stibitz; Karen L Elkins; Tod J Merkel
Journal:  Infect Immun       Date:  2013-02-04       Impact factor: 3.441

8.  Bacillus anthracis has two independent bottlenecks that are dependent on the portal of entry in an intranasal model of inhalational infection.

Authors:  David E Lowe; Stephen M C Ernst; Christine Zito; Jason Ya; Ian J Glomski
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

9.  Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant.

Authors:  Brandon Feinen; Nikolai Petrovsky; Anita Verma; Tod J Merkel
Journal:  Clin Vaccine Immunol       Date:  2014-02-19

10.  Nod1/Nod2-mediated recognition plays a critical role in induction of adaptive immunity to anthrax after aerosol exposure.

Authors:  Crystal L Loving; Manuel Osorio; Yun-Gi Kim; Gabriel Nuñez; Molly A Hughes; Tod J Merkel
Journal:  Infect Immun       Date:  2009-07-20       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.